Company intelligence / Profile preview

Cell Science & Technology Institute

Japan

Ownership: Private
Development stage: Other

Overview

CSTI creates and supplies high-performance, serum-free cell culture media to support cell therapies, stem cell research, and biopharmaceutical manufacturing, with a focus on safety and compatibility for advanced medical research and commercial manufacturing.

Therapeutic areas: HematologyOtherOncology
Modalities: Cell therapyStem cell therapyMonoclonal antibodyVaccineRecombinant proteinBiologicSmall molecule
Industry: Chemicals & Materials

Partnerships

Iwai North America Inc. (distribution partner)

Beyond the preview

Go deeper on Cell Science & Technology Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell Science & Technology Institute.

Explore the full profile